vs
EXACT SCIENCES CORP（EXAS）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是RANGE RESOURCES CORP的1.1倍（$878.4M vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs -9.8%，领先32.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 18.0%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 14.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
EXAS vs RRC — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$786.9M
营收增速更快
EXAS
高出5.1%
18.0%
净利率更高
RRC
高出32.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
14.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $786.9M |
| 净利润 | $-86.0M | $179.1M |
| 毛利率 | 70.1% | 94.5% |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.8% | 22.8% |
| 营收同比 | 23.1% | 18.0% |
| 净利润同比 | 90.1% | 88.8% |
| 每股收益（稀释后） | $-0.45 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRRC
| Q4 25 | $878.4M | $786.9M | ||
| Q3 25 | $850.7M | $655.3M | ||
| Q2 25 | $811.1M | $699.6M | ||
| Q1 25 | $706.8M | $846.3M | ||
| Q4 24 | $713.4M | $667.0M | ||
| Q3 24 | $708.7M | $567.9M | ||
| Q2 24 | $699.3M | $513.2M | ||
| Q1 24 | $637.5M | $598.8M |
净利润EXASRRC
| Q4 25 | $-86.0M | $179.1M | ||
| Q3 25 | $-19.6M | $144.3M | ||
| Q2 25 | $-1.2M | $237.6M | ||
| Q1 25 | $-101.2M | $97.1M | ||
| Q4 24 | $-864.6M | $94.8M | ||
| Q3 24 | $-38.2M | $50.7M | ||
| Q2 24 | $-15.8M | $28.7M | ||
| Q1 24 | $-110.2M | $92.1M |
毛利率EXASRRC
| Q4 25 | 70.1% | 94.5% | ||
| Q3 25 | 68.6% | 92.5% | ||
| Q2 25 | 69.3% | 95.0% | ||
| Q1 25 | 70.8% | 93.1% | ||
| Q4 24 | 69.0% | 93.7% | ||
| Q3 24 | 69.4% | 94.3% | ||
| Q2 24 | 69.8% | 93.4% | ||
| Q1 24 | 70.0% | 94.7% |
营业利润率EXASRRC
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | — |
净利率EXASRRC
| Q4 25 | -9.8% | 22.8% | ||
| Q3 25 | -2.3% | 22.0% | ||
| Q2 25 | -0.1% | 34.0% | ||
| Q1 25 | -14.3% | 11.5% | ||
| Q4 24 | -121.2% | 14.2% | ||
| Q3 24 | -5.4% | 8.9% | ||
| Q2 24 | -2.3% | 5.6% | ||
| Q1 24 | -17.3% | 15.4% |
每股收益（稀释后）EXASRRC
| Q4 25 | $-0.45 | $0.75 | ||
| Q3 25 | $-0.10 | $0.60 | ||
| Q2 25 | $-0.01 | $0.99 | ||
| Q1 25 | $-0.54 | $0.40 | ||
| Q4 24 | $-4.69 | $0.38 | ||
| Q3 24 | $-0.21 | $0.21 | ||
| Q2 24 | $-0.09 | $0.12 | ||
| Q1 24 | $-0.60 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $2.4B | $4.3B |
| 总资产 | $5.9B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资EXASRRC
| Q4 25 | $964.7M | $204.0K | ||
| Q3 25 | $1.0B | $175.0K | ||
| Q2 25 | $858.4M | $134.0K | ||
| Q1 25 | $786.2M | $344.6M | ||
| Q4 24 | $1.0B | $304.5M | ||
| Q3 24 | $1.0B | $277.4M | ||
| Q2 24 | $946.8M | $251.1M | ||
| Q1 24 | $652.1M | $343.1M |
总债务EXASRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益EXASRRC
| Q4 25 | $2.4B | $4.3B | ||
| Q3 25 | $2.5B | $4.2B | ||
| Q2 25 | $2.5B | $4.1B | ||
| Q1 25 | $2.4B | $3.9B | ||
| Q4 24 | $2.4B | $3.9B | ||
| Q3 24 | $3.2B | $3.9B | ||
| Q2 24 | $3.2B | $3.9B | ||
| Q1 24 | $3.1B | $3.8B |
总资产EXASRRC
| Q4 25 | $5.9B | $7.4B | ||
| Q3 25 | $5.9B | $7.2B | ||
| Q2 25 | $5.8B | $7.1B | ||
| Q1 25 | $5.7B | $7.4B | ||
| Q4 24 | $5.9B | $7.3B | ||
| Q3 24 | $6.7B | $7.2B | ||
| Q2 24 | $6.7B | $7.3B | ||
| Q1 24 | $6.4B | $7.4B |
负债/权益比EXASRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRRC
| Q4 25 | $151.7M | $257.5M | ||
| Q3 25 | $219.9M | $247.5M | ||
| Q2 25 | $89.0M | $336.2M | ||
| Q1 25 | $30.8M | $330.1M | ||
| Q4 24 | $47.1M | $217.9M | ||
| Q3 24 | $138.7M | $245.9M | ||
| Q2 24 | $107.1M | $148.8M | ||
| Q1 24 | $-82.3M | $331.9M |
自由现金流EXASRRC
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASRRC
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASRRC
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASRRC
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
